Sarcoma  >>  elimusertib (BAY 1895344)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elimusertib (BAY 1895344) / Bayer
PEPN2112, NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Active, not recruiting
1/2
23
Canada, US
Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344
National Cancer Institute (NCI)
Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
12/24
12/24

Download Options